ImmunoPrecise Antibodies : Investor Presentation August 2022

Full Speed Ahead

to Personalized Medicine.

August 2022| NASDAQ:IPA

At-A-Glance

Corporate profile

IPA is an innovative, scientific Contract Research Organization (CRO) recently ranked by one of the pharmaceutical industry's most trusted, independent market research sources with the highest

Capital Structure (all values in CAD unless otherwise noted)

(NASDAQ: IPA); (TSXV: IPA)

SHARES DATA, 2021 (as of July 31, 2022)

BALANCES (as of April 30, 2022)

competitive score for its antibody service portfolio.1

We own a proprietary set of highly specialized technologies used to customize the successful discovery of complex and novel therapies along every step of the development process.

Our services are supported with advanced omics and complex intelligence technology, providing unparalleled accuracy

in personalized medicine.

1. ROOTS 2022: Antibody Discovery Services and Platforms Market (Industry Trends and Global Forecast, 4th Edition), 2021-2035​; p.118

Shares Outstanding	24,836,723
Share Price (CAD)	$5.29
Market Cap	$131,386,265

WARRANTS (as of April 30, 2022)

Balance	Weighted	Weighted	Future Cash
	Average Exercise	Average Life	Opportunity
	Price	Remaining
		(Years)
130,111(1)	$16.81	3.77	$2,187,166

(1) Price and cash value stated in USD

Cash on Hand	$29,964,898

OPTIONS (as of April 30, 2022)

		Weighted	Weighted Average
	Balance	Average	Life Remaining
		Exercise Price	(Years)
Exercisable	1,094,296	$7.64	2.16
Unvested	529,854	$9.63	4.35
Total	1,624,150	$8.29	2.88

©2022 ImmunoPrecise Antibodies. All Rights Reserved. CONFIDENTIAL	2

IPA - Twelve Month Selected Highlights

Milestones and Achievements in a Year

• RANKED #1 global CRO in leading market analysis1
• ACQUIRED BioStrand with disruptive multi-omic analysis software, IP for universal omic language patterns

*Universal fingerprints to enable the selection of any biologic sequence based on activity

*Patent-pending technology aimed at disrupting multiple industries (therapeutic discovery, healthcare, AI, quantum computing, agriculture, etc).

• Eurofins Discovery signs service and marketing collaboration
• Pierre Fabre partners for multi-target antibody

discovery research collaboration in oncology

• ONLY REMAINING efficacious 1st generation therapy against all tested variants of concern
• DOD supported program with Elektrofi for pandemic preparedness

1. ROOTS 2022: Antibody Discovery Services and Platforms Market (Industry Trends and Global Forecast, 4th Edition), 2021-2035​; p.118

©2022 ImmunoPrecise Antibodies. All Rights Reserved. CONFIDENTIAL	3

Antibody discovery platforms - engineered for the scientific race

Integrated End-to-End Technologies

Known for robust technologies with clinically relevant outcomes

• Exceptional diversity of candidates
• Sequences associated with
  FUNCTION
• Leading custom B-Cell platforms and Deep Phage technologies
• Workflow efficiency and speed [powered by LENSai™]
• Fast growing - over 600 clients,

80% of top 20 pharma

©2022 ImmunoPrecise Antibodies. All Rights Reserved. CONFIDENTIAL	4

Global Players and Partners

Chosen and respected by industry leaders and titans

©2022 ImmunoPrecise Antibodies. All Rights Reserved. CONFIDENTIAL	5